Welcome to our dedicated page for MindWalk Holdings SEC filings (Ticker: HYFT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MindWalk Holdings Corp. filings document a foreign private issuer that furnishes Form 6-K reports for U.S. market disclosure. The company’s regulatory record includes earnings releases, IFRS-tagged financial data, press releases on Bio-Native AI platform developments, and exhibits covering technologies such as LensAI, HYFT, and B Cell Llama.
The filings also disclose capital-structure and governance items, including issued capital, restricted share units, stock options, lease liabilities, product sales, internally generated development costs, and corporate segment data. Separate 6-K submissions provide SEDI insider activity reports, reflecting the company’s foreign private issuer treatment and exemption from Section 16 Form 4 reporting requirements.
MindWalk Holdings Corp., a British Columbia-based Bio-Native AI drug-discovery company listed on Nasdaq as “HYFT”, has filed an amended shelf registration allowing it to offer up to $250,000,000 of common shares, future preferred shares, debt securities, warrants, units and subscription receipts over a 36‑month period. A dedicated sales agreement prospectus supplement covers common shares that may be sold under a $50,000,000 at-the-market program, which is part of the overall $250 million capacity. As of April 30, 2026, 46,711,866 common shares were outstanding, and a Board-authorized repurchase program permits buybacks of up to 2.3 million shares.
The company positions its patented HYFT biological pattern technology and LensAI and ReefIQ platforms as an integrated AI-plus-wet-lab ecosystem supporting biologics discovery, an internal AI-designed asset pipeline, and a portfolio of 16 partner-ready biologics assets. Recent developments include an at-the-market equity offering program under which 800,899 shares have been sold for gross proceeds of $1.39 million and the sale of ImmunoPrecise Antibodies (Europe) B.V. for approximately $12 million. The filing highlights potential dilution from future issuances, limited trading markets for non-common-share securities, changing U.S. tax laws, and the company’s status as a foreign private issuer using IFRS.
MindWalk Holdings Corp. presented the first public demonstration of its ReefIQ biological context layer for AI drug discovery, running on AMD Instinct at AMD’s Advancing AI 2026 in San Francisco. ReefIQ reconnects fragmented life-sciences data into governed, queryable biological context that AI models and agents can reason over.
ReefIQ is built on MindWalk’s HYFT Technology, a biological representation curated over 20 years that spans 660 million biological patterns and 25 billion relationships, with LensAI providing the reasoning layer. MindWalk’s team plans to use the event to engage life-sciences customers, infrastructure partners, and agentic-AI builders, and notes that LensAI is already used in contracted, recurring arrangements.
MindWalk Holdings Corp., an AI-driven biopharmaceutical discovery company listed on Nasdaq as HYFT, reports 46,711,866 Common Shares outstanding as of April 30, 2026. It prepares IFRS financial statements in Canadian dollars and qualifies as a foreign private issuer, with comparatively reduced U.S. reporting obligations.
The company highlights significant liquidity pressure: it has negative operating cash flows, does not have sufficient cash reserves to fund operations for the next twelve months, and states this raises substantial doubt about its ability to continue as a going concern. Management expects operating costs to increase as it builds the LensAI and HYFT AI platforms and has identified a material weakness in internal control over financial reporting.
To support funding needs, MindWalk established a U.S.$300 million shelf, completed a U.S.$1.265 million underwritten share offering at U.S.$1.00 per share, and used at-the-market programs to sell additional shares. Strategy increasingly centers on commercializing AI-enabled software and data platforms while continuing contract research services, amid extensive operational, regulatory, cybersecurity, intellectual-property, market and governance risks.
MindWalk Holdings Corp. reported preliminary fiscal 2026 results, with revenue rising 46% to C$15.6 million and gross margin expanding to 58.8%. Net loss from continuing operations improved to C$15.1 million and overall net loss to C$13.9 million, while loss per share from continuing operations narrowed to C$0.33 from C$0.99. Figures are preliminary and subject to completion of the Annual Report on Form 20-F.
Operating expenses fell to C$24.1 million, mainly because C$22.7 million of prior-year amortization and impairment charges did not recur, while R&D, sales and marketing, and G&A all increased as MindWalk invested in its Bio-Native AI platform. Total cash, cash equivalents, marketable securities and restricted cash were C$11.5 million as of April 30, 2026. The company completed its rebranding from ImmunoPrecise Antibodies, divested its Netherlands subsidiary for about C$14.3 million, regained Nasdaq listing compliance, authorized a buyback of up to 2.3 million shares, signed its first two recurring LensAI agreements, and subsequently launched ReefIQ and secured Russell index inclusion.
MindWalk Holdings Corp., a British Columbia-based foreign private issuer traded on Nasdaq as HYFT, has filed a replacement shelf registration statement on Form F-3 to offer up to $250,000,000 of common shares, preferred shares, debt securities, warrants, units and subscription receipts over a 36‑month period. The filing is made under Rule 415(a)(6) to replace an earlier F-3 while unsold securities under the prior registration remain available until the earlier of this new statement’s effectiveness or January 10, 2027.
The base shelf includes a dedicated sales agreement prospectus for up to $50,000,000 of common shares under a sales agreement, and the company separately maintains an at‑the‑market program of up to $30,000,000, under which 779,368 shares have been sold for $1.36 million. Shares outstanding were 46,711,866 as of January 31, 2026, and the board has authorized repurchases of up to 2.3 million shares. MindWalk describes itself as a Bio‑Native AI company built around its patented HYFT biological pattern technology and LensAI/ReefIQ platforms, with internal AI‑designed therapeutic programs and a portfolio of partner‑ready biologics assets. Net proceeds from any offerings are intended for working capital, general corporate purposes and advancing its business objectives.
MindWalk Holdings Corp., a Bio-Native AI company listed on NASDAQ under HYFT, plans to report financial results for the fourth quarter and full fiscal year 2026 on July 22, 2026. Management will host a conference call and webcast that day at 5:00 p.m. Eastern Time, with a press release to be issued beforehand.
The business integrates AI, data, and advanced wet lab capabilities into a connected discovery ecosystem built on its proprietary HYFT Technology, a function-aware representation of biology underpinning its ReefIQ and LensAI platforms. The company highlights that its forward-looking statements are subject to various risks, including technology performance, market acceptance, partnerships, competition, regulatory outcomes, and capital markets conditions.
MindWalk Holdings Corp. reports that its shares have been added to the Russell 3000E Index, effective after the U.S. market close on June 26, 2026, as part of FTSE Russell’s June 2026 semi-annual reconstitution. Membership was reconfirmed in index data published June 29, 2026.
The Russell 3000E Index covers up to 4,000 of the largest U.S.-domiciled public companies by market capitalization. Inclusion makes MindWalk eligible for passive ownership by index-tracking funds and other vehicles that follow this benchmark and broader indexes built from it. FTSE Russell states that about USD 12.2 trillion in investor assets are benchmarked to or invested in products based on the Russell US Indexes.
MindWalk describes itself as a Bio-Native AI company built around its proprietary HYFT Technology, which encodes a curated biological representation of 660 million patterns and 25 billion relationships. This underpins its ReefIQ data substrate and LensAI reasoning layer, which support life sciences discovery, diligence, and portfolio decision workflows.
MindWalk Holdings Corp. filed European patent application No. EP26187897.9 covering a high-dimensional biological data architecture that underpins its HYFT® Technology, ReefIQ™ context layer, and LensAI™ AI workflows for drug discovery. The patent targets how biological subsequences and their properties are represented so AI agents can retrieve, compare, and reason over connected, traceable biology.
The application is described as a distinct, additive layer built on MindWalk’s existing HYFT® patent estate, aiming to keep sequence, structure, physicochemical, functional, experimental, and literature context organized around recurring biological patterns. MindWalk highlights active preclinical dengue and influenza programs and notes that LensAI™ is already in contracted, recurring use with life-sciences customers.
MindWalk Holdings Corp. filed a Form 6-K highlighting a press release that its President and CEO, Dr. Jennifer Bath, will join a Jones AI Day virtual panel on June 15, 2026, focused on the future of AI-driven drug discovery.
The event will examine how high-performance compute, native biological knowledge representations, and generative and agentic AI can address long-standing drug discovery challenges. MindWalk describes its HYFT® system, which powers ReefIQ™, as a biological context layer built on 25 years of wet-lab expertise, organizing 660 million biological patterns and 25 billion relationships.
Its LensAI™ platform runs on this infrastructure to support target discovery, candidate diligence, portfolio decisions, and agentic AI workflows. MindWalk notes LensAI is already used in contracted, recurring arrangements with life-sciences customers and includes extensive forward-looking statements language outlining assumptions and risks around adoption, infrastructure, competition, and regulation.
MindWalk Holdings Corp. announced the launch of ReefIQ™, a HYFT-powered biological context layer that connects fragmented drug-discovery data to AI reasoning workflows. ReefIQ links sequences, structures, assays, omics, literature, evidence, provenance, and program history into governed, queryable biological context for AI-enabled discovery.
The platform sits between client discovery data and AI models, feeding MindWalk’s LensAI™ reasoning layer and customer-selected agent models. HYFT® provides the underlying biological representation, while ReefIQ harmonizes customer data and governance, and LensAI applies retrieval, analysis, target discovery, candidate diligence, hypothesis generation, and portfolio decision support.
MindWalk positions ReefIQ as the foundation for future life-sciences engagements, with architecture designed for flexible integration across data governance, model access, and compute deployment. The company notes that LensAI is already used in contracted, recurring arrangements with life-sciences customers.